Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2023-08-28
Target enrollment:
Participant gender:
Summary
This phase I trial is to find out the best dose, possible benefits, and/or side effects of
hypofractionated radiation therapy and bintrafusp alfa in treating patients with bile duct
cancer that has spread to other places in the body (advanced intrahepatic
cholangiocarcinoma). Hypofractionated radiation therapy delivers higher doses of radiation
therapy over a shorter period of time and may kill more tumor cells and have fewer side
effects. Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the
monoclonal antibody avelumab and TGF-beta, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. The combination
of hypofractionated radiation therapy and bintrafusp alfa may help to control intrahepatic
cholangiocarcinoma.